Levomilnacipran

Indications

• FDA-approved only for major depressive disorder in adults, at 40-120 mg once daily after a brief 20 mg lead-in.
• Not approved for any anxiety, pain, or pediatric indication, which distinguishes it sharply from duloxetine and venlafaxine.
• Its enantiomer milnacipran is approved in the United States for fibromyalgia, but levomilnacipran itself has no pain indication.
• Often selected off-label when fatigue, apathy, and impaired concentration dominate the depressive presentation.
• Fixed-dose trials showed benefit at 40, 80, and 120 mg/day, with the number needed to treat for response near 8 to 10.
• Not a first-line agent in major guidelines, given its cost, cardiovascular effects, and lack of comparative advantage over SSRIs.

Mechanism of action

• Inhibits both monoamine transporters but with roughly twofold greater potency at the norepinephrine transporter than at the serotonin transporter.
• That reversed selectivity is unique among marketed SNRIs, all of which are otherwise more serotonergic than noradrenergic.
• Predominant noradrenergic action is the rationale for its use in depression marked by low energy, apathy, and poor concentration.
• The same noradrenergic tone produces the heart rate rise, hypertension, hyperhidrosis, and urinary hesitancy seen in trials.
• It is the active levo-enantiomer of milnacipran and has no meaningful muscarinic, histaminic, or adrenergic receptor blockade.

Pharmacokinetics

• Absolute bioavailability is about 92 percent and is unaffected by food, so the extended-release capsule may be taken with or without meals.
• Half-life is approximately 12 hours, with once-daily extended-release dosing and steady state reached in two to three days.
• Roughly 58 percent of a dose is excreted unchanged in urine, which is why renal function drives the maximum permitted dose.
• Hepatic metabolism proceeds mainly through CYP3A4, with minor contributions from CYP2C8, 2C19, 2D6, and 2J2 and no active metabolites.
• It does not meaningfully inhibit or induce CYP enzymes, so it rarely alters the concentration of co-prescribed medications.

Dosing

• Start 20 mg PO once daily for two days, then increase to 40 mg once daily, which is the minimum effective dose.
• Titrate by 40 mg increments at intervals of at least two days; the effective range is 40 to 120 mg/day and the maximum is 120 mg/day.
• Reduce the maximum to 80 mg/day in moderate renal impairment and to 40 mg/day in severe impairment; avoid in end-stage renal disease.
• Cap the dose at 80 mg/day when a strong CYP3A4 inhibitor such as ketoconazole, clarithromycin, or ritonavir is co-prescribed.
• Supplied as 20, 40, 80, and 120 mg extended-release capsules that must be swallowed whole, not opened, chewed, or crushed.
• Taper gradually rather than stopping abruptly, since the 12 hour half-life makes discontinuation symptoms likely.

Adverse effects

• Nausea occurs in about 17 percent of patients, with constipation, vomiting, and decreased appetite also common early in treatment.
• Heart rate rises by roughly 7 beats per minute on average, and palpitations or tachycardia are among the more frequent complaints.
• Blood pressure increases modestly and dose-dependently, so uncontrolled hypertension should be corrected before initiation.
• Urinary hesitancy and retention are more common than with other SNRIs and reflect the drug's noradrenergic dominance.
• Erectile dysfunction, ejaculatory disorder, and hyperhidrosis are frequent and often lead patients to request a switch.
• Serotonin syndrome, hyponatremia, mydriasis with angle-closure risk, and increased bleeding are the serious prescribing concerns.

Monitoring

• Measure heart rate and blood pressure at baseline, after each dose increase, and periodically during maintenance treatment.
• Estimate creatinine clearance before starting, since renal function sets the dose ceiling and end-stage disease precludes use.
• Ask specifically about urinary hesitancy and incomplete emptying, particularly in men with benign prostatic hyperplasia.
• Assess suicidality, activation, and agitation weekly for the first four weeks and after each dose change, especially under age 25.
• Track response with the PHQ-9 or MADRS every two to four weeks and reassess if there is no change by week six at 80 mg/day.

Interactions

• Contraindicated with MAOIs and within 14 days of stopping one, and with linezolid or intravenous methylene blue.
• Strong CYP3A4 inhibitors raise exposure and require the dose to be capped at 80 mg/day for as long as they are co-prescribed.
• Strong CYP3A4 inducers such as carbamazepine, rifampin, and phenytoin can reduce concentrations and cause apparent nonresponse.
• Additive noradrenergic effects with stimulants, atomoxetine, and decongestants can produce clinically significant tachycardia.
• Additive serotonin syndrome risk with triptans, tramadol, fentanyl, and lithium, and additive bleeding risk with NSAIDs and anticoagulants.

Special populations

• Pregnancy data are very limited, so a better-characterized antidepressant should generally be chosen when treatment is needed in gestation.
• Lactation data are essentially absent; if breastfeeding, choose an agent with an established infant safety record instead.
• Not approved for pediatric use, and no adequate controlled trials in children or adolescents have been published.
• In older adults titrate cautiously and monitor heart rate, blood pressure, urinary retention, and hyponatremia more closely.
• Renal impairment governs dosing: 80 mg/day maximum at moderate impairment, 40 mg/day at severe, and avoid in end-stage disease.

Clinical pearls

• The only SNRI that is more noradrenergic than serotonergic, so think energy, focus, and blood pressure.
• Ask men about urinary hesitancy before and after starting; retention is the distinguishing side effect.
• Renal function sets the ceiling: 80 mg/day if moderate impairment, 40 mg/day if severe.